| 1849 |
Nodal DR-TB Centre Committee |
02/06/2024 |
DR-TB and PMDT |
| 1855 |
NTEP Services for Private Notified DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1856 |
Inclusion and Exclusion Criteria for the Use of Bedaquiline |
02/06/2024 |
DR-TB and PMDT |
| 1857 |
Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Drug Dose Administration |
02/06/2024 |
DR-TB and PMDT |
| 1858 |
Key Considerations for the Use of Bedaquiline [Bdq] |
02/06/2024 |
DR-TB and PMDT |
| 1859 |
Follow-up Monitoring of DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1860 |
Follow-up Evaluation of Patients on Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1861 |
Principles for Management of MDR/RR-TB in Children |
02/06/2024 |
DR-TB and PMDT |
| 1862 |
DR-TB Treatment in Pregnancy: Recommendation for the Use of Contraception |
02/06/2024 |
DR-TB and PMDT |
| 1863 |
Role of Surgery in DR-TB Treatment |
02/06/2024 |
DR-TB and PMDT |
| 1864 |
Use of M/XDR-TB Regimen in Patients with Seizure Disorders |
02/06/2024 |
DR-TB and PMDT |
| 1865 |
Use of M/XDR-TB Regimen in Patients with Psychiatric Illness |
02/06/2024 |
DR-TB and PMDT |
| 1866 |
Treatment Extension in Longer Oral M/XDR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1867 |
Additional Considerations for the Use of Newer Drugs in Longer Oral M/XDR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 6327 |
Multiple BCG vaccination Policy- Countrywise profile |
02/06/2024 |
BCG Vaccine |
| 6137 |
Adult BCG[aBCG] vaccine |
02/06/2024 |
|
| 6135 |
Rationale for Adult BCG vaccination in India |
02/06/2024 |
TB Vaccines |
| 6133 |
Safety profile of BCG Vaccine |
02/06/2024 |
TB Vaccines |
| 2628 |
Sequence of Using Replacement Drugs to Modify the Longer Oral M/XDR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1869 |
Management of DR-TB ADR: QT Prolongation |
02/06/2024 |
DR-TB and PMDT |
| 1870 |
Management of ADR: Rash, Allergy and Anaphylaxis Reaction |
02/06/2024 |
DR-TB and PMDT |
| 1871 |
Management of DR-TB ADR: Hepatitis |
02/06/2024 |
DR-TB and PMDT |
| 1872 |
Management of DR-TB ADR: Peripheral Neuropathy |
02/06/2024 |
DR-TB and PMDT |
| 1873 |
Management of DR-TB ADR: Vestibular Toxicity |
02/06/2024 |
DR-TB and PMDT |
| 1874 |
Management of DR-TB ADR: Optic Neuritis |
02/06/2024 |
DR-TB and PMDT |
| 1875 |
Management of DR-TB ADR: Electrolyte Disturbances |
02/06/2024 |
DR-TB and PMDT |
| 1876 |
Management of DR-TB ADR: Alopecia |
02/06/2024 |
DR-TB and PMDT |
| 1877 |
Management of DR-TB ADR: Superficial Fungal Infection and Thrush |
02/06/2024 |
DR-TB and PMDT |
| 1878 |
Management of DR-TB ADR: Lactic Acidosis |
02/06/2024 |
DR-TB and PMDT |
| 1879 |
Management of DR-TB ADR: Dysglycaemia and Hyperglycemia |
02/06/2024 |
DR-TB and PMDT |
